Free
Critical Care Medicine  |   June 2011
Pioglitazone Attenuates Acute Cocaine Toxicity in Rat Isolated Heart: Potential Protection by Metabolic Modulation
Author Affiliations & Notes
  • Guy L. Weinberg, M.D.
    *
  • Richard Ripper, C.V.T.
  • Sarah Bern, B.A.
  • Bocheng Lin, M.B.A.
  • Lucas Edelman, B.A.
    §
  • Guido DiGregorio, M.D., Ph.D.
  • Mariann Piano, Ph.D.
    #
  • Douglas L. Feinstein, Ph.D.
    **
  • * Professor, Department of Anesthesiology, University of Illinois College of Medicine at Chicago and Jesse Brown Veterans Administration Medical Center, Chicago, Illinois; † Senior Research Associate, ‡ Research Assistant, Department of Anesthesiology, University of Illinois College of Medicine; ** Research Professor, Department of Anesthesiology, # Professor, Department of Biobehavioral Health Sciences, University of Illinois College of Medicine at Chicago; § Graduate Student, Department of Bioinformatics, Cambridge University, Cambridgeshire, England; ∥ Department of Anesthesiology, and Intensive Care, Azienda Ospedaliera Padova, Padua, Italy.
Article Information
Critical Care Medicine / Cardiovascular Anesthesia / Critical Care
Critical Care Medicine   |   June 2011
Pioglitazone Attenuates Acute Cocaine Toxicity in Rat Isolated Heart: Potential Protection by Metabolic Modulation
Anesthesiology 6 2011, Vol.114, 1389-1395. doi:10.1097/ALN.0b013e318218a7f6
Anesthesiology 6 2011, Vol.114, 1389-1395. doi:10.1097/ALN.0b013e318218a7f6
What We Already Know about This Topic
  • Bupivacaine depresses myocardial function in part by impairing mitochondrial fatty acid uptake, but whether cocaine also causes this effect is not known

  • Pioglitazone, a treatment for diabetes mellitus, could reverse this effect by reducing local anesthetic actions on mitochondria

What This Article Tells Us That Is New
  • In isolated rat hearts and tissues, cocaine inhibited mitochondrial respiration

  • Pioglitazone treatment partially prevented the cardiotoxic effects of cocaine.

COCAINE, a local anesthetic with potent sympathomimetic properties, is a common drug of abuse in the United States, and acute cocaine intoxication is a common cause of emergency department visits. Patients often present with hypertension, arrhythmias, and chest pain—a clinical equivalent to acute coronary syndrome. Cocaine induces ischemia by concomitant systemic and coronary arterial vasoconstriction, which causes imbalance in the myocardial oxygen supply-demand ratio.1,2 Severe cocaine toxicity is also associated with myocardial contractile depression, but the mechanisms underlying this effect are not clearly established.3 We previously have shown that bupivacaine, another cardiotoxic local anesthetic, impairs mitochondrial uptake of fatty acid substrates through inhibition of acylcarnitine exchange.4 This effect is postulated to contribute to bupivacaine-induced myocardial toxicity. In the current study, we tested the hypothesis that cocaine similarly impairs mitochondrial fatty acylcarnitine metabolism and ascertained whether a strategy of metabolic modulation could reduce the cardiotoxic effects of cocaine.
Pioglitazone is a member of the thiazolidinedione class of peroxisome proliferator-activated receptor-γ agonists currently used for treatment of type 2 diabetes.5 Peroxisome proliferator-activated receptor-γ activation plays a critical role in energy homeostasis by modulating insulin sensitivity in both adipose and muscle tissue.6 We previously showed that thiazolidinediones increase glucose consumption and lactate production in cultured astrocytes and exhibit cytoprotection against hypoglycemia-induced cell death.7 Thiazolidinediones have also been found to exert multiple transcription-independent effects, including regulation of mitochondrial function by altering complex I of the respiratory chain.8 The heart, like the central nervous system, is highly dependent on aerobic metabolism to maintain cell function and viability. We postulated that pretreatment with pioglitazone as a dietary additive could attenuate subsequent cocaine-induced cardiac toxicity by reducing sensitivity to mitochondrial metabolic challenges.
Materials and Methods
Rats
Adult male Sprague-Dawley rats, weighing between 450 and 550 g (3–4 months old) were used in all experiments. All protocols were approved by the Animal Care Committee of the University of Illinois Office for Protection of Research Subjects (Chicago, Illinois) and by the Institutional Animal Care and Use Committee of the Veterans Administration Chicago Healthcare System (Chicago, Illinois).
Pioglitazone Treatment
Rats were fed ad libitum  either standard chow or chow containing pioglitazone, 100 ppm, equivalent to low micromolar serum concentrations9 for 1 week before the experiments.
Mitochondrial Studies
Cardiac interfibrillar mitochondria were prepared from a homogenate of rat cardiac ventricles by differential centrifugation according to the procedure of Palmer et al  .10 Respiration was measured at 30°C in a 0.5-ml chamber containing mitochondria in a final concentration of 1 mg protein/ml. After equilibration of the Clark oxygen electrode probe (YSI Clark Oxygen Probe, Yellow Springs, OH), endogenous mitochondrial substrates were depleted by addition of 0.1 mM adenosine diphosphate. Respiration was then initiated by the addition of substrate to the incubation medium. Mitochondrial oxygen use was monitored during pyruvate-stimulated respiration (n = 6) and octanoylcarnitine-stimulated respiration (n = 6) by measuring the rate of decrease of oxygen concentration in the chamber. Calculations of respiratory rates, in units of ngatomO min−1· mg−1· protein, were derived from the slope of oxygen concentration in the reaction chamber.
Isolated Heart System
Rats were anesthetized by intraperitoneal injection of 60 mg/kg sodium pentobarbital (Abbott Labs, Abbott Park, IL), and after systemic heparinization, hearts were removed, cannulated through the ascending aorta, suspended from a Langendorff apparatus and perfused at a constant rate of 16 ml/min with Krebs-Ringer bicarbonate buffer (KRB) containing 100.00 mM NaCl, 4.74 mM KCl, 1.18 mM KH2PO4, 1.18 mM MgSO4, 1.00 mM CaCl2, 25.00 mM NaHCO3, 11.50 mM glucose, 4.92 mM pyruvate, and 5.39 mM fumarate with pH 7.40 via  roller pump. KRB perfusate was warmed in the Langendorff apparatus by countercurrent flow from a 37°C water bath, and the temperature of the KRB was continuously measured just above the heart and maintained at 37°C. The heart was suspended inside a glass cylinder warmed by the same countercurrent. KRB was also equilibrated with a mixture of oxygen (95%) and carbon dioxide (5%) by passage through a membrane oxygenator.
Monitoring Cardiac Function
Pressure data from a latex balloon in the left ventricle connected to a pressure transducer were recorded, archived, and analyzed by Powerlab Data Analysis System using Chart 5.2.1 (ADInstruments, Colorado Springs, CO). A catheter was placed in the pulmonary artery to sample outflow from the coronary circulation for determining venous Po2.
Metabolic and Functional Parameters
Heart rate, left ventricular developed pressure (systolic pressure − diastolic pressure), the maximum positive rate of change in left ventricular pressure (dP/dtmax), rate-pressure product (RPP; RPP = heart rate × left ventricular developed pressure) and the left ventricular relaxation time constant (τ) were continuously monitored throughout the experiment. The perfusate was sampled above the heart and from the pulmonary artery catheter to calculate oxygen consumption (oxygen consumption = coronary flow × 0.024 ×[Po2arterial− Po2venous]).
Lactate Measurements
To assess lactate production, samples were incubated with 90 μl ς Diagnostic Lactate (Sigma–Aldrich Corp., St. Louis, MO) reagent, for 20 min at room temperature, and absorbance was read at 550 nm. In each assay, a standard curve was prepared in the range of 0–100 mg/100 ml D-glucose or 0–50 mg/100 ml L-lactate in Dulbecco's Modified Eagle's Media. Concentrations in each sample were calculated by interpolation from these standard curves.
Cell Culture
Rat ventricular myocytes (H9C2) were obtained from the American Type Culture Collection (Manassas, VA) and grown in Dulbecco's Modified Eagle's Media containing 10% fetal calf serum (GIBCO Life Technologies, Gaithersburg, MD) and antibiotics. Cell culture reagents were from Sigma–Aldrich Corporation.
Cocaine Infusion Protocol
After the hearts were stabilized for 20 min on the Langendorff apparatus, a solution of cocaine hydrochloride was infused through a port 2 cm above the heart at a rate calculated to achieve a final concentration of 10 μM in the buffer. The infusion was continued for 5 min then increased sequentially to attain final concentrations of 50 μM and 100 μM, each for 5 min. These concentrations are typical of in vitro  cardiac11 and sodium channel12 studies of cocaine and blood concentrations at postmortem examination in fatal cocaine overdose.13 
Statistical Analysis
All data sets were imported and analyzed in GraphPad Prism 5 (GraphPad Software, San Diego, CA). A two-tailed unpaired t  test with Welch's correction was used to compare respiratory rates of different groups of mitochondria. Heart rate, rate-pressure product, left ventricular relaxation rate constant (τ), left ventricular end-diastolic pressure, oxygen consumption, and lactate production were each analyzed for the control and pioglitazone treatment groups at baseline using two-tailed, unpaired t  test with Welch's correction. During cocaine infusions, between-group differences in parameters were analyzed at 0, 10, 50, and 100 μM cocaine using repeated measures two-way ANOVA with Bonferroni posttests when P  < 0.05.
Results
Mitochondrial Studies
We compared the effects of 0.5 mM cocaine on respiration supported by either pyruvate or octanoylcarnitine (n = 6 for both groups in all experiments except lactate concentration, for which n = 5 for both control and pioglitazone groups). Rates of oxygen consumption during pyruvate-supported respiration were the same for control and cocaine-treated groups (281 ± 12.5 and 267 ± 12.7 ngatomO min−1· mg−1· protein ± SEM, respectively; P  = 0.45; fig. 1). However, the respiratory rates during octanoylcarnitine-supported respiration for control and cocaine-treated groups were 82 ± 10.4 and 45.7 ± 4.24 ngatomO min−1· mg−1· protein ± SEM, respectively (P  < 0.02). Thus, at 0.5 mM, cocaine inhibits lipid-based respiration in cardiac mitochondria by roughly 50%.
Fig. 1.  Cocaine impairs lipid-based respiration. Mean values are plotted, and error bars indicate SEM. *P  < 0.05; n = 6 for both groups.
Fig. 1. 
	Cocaine impairs lipid-based respiration. Mean values are plotted, and error bars indicate SEM. *P 
	< 0.05; n = 6 for both groups.
Fig. 1.  Cocaine impairs lipid-based respiration. Mean values are plotted, and error bars indicate SEM. *P  < 0.05; n = 6 for both groups.
×
Isolated Heart Experiments
Functional Parameters
Baseline values of RPP, line pressure, τ, and left ventricular end-diastolic pressure were not different between the control and pioglitazone-treated hearts (n = 6 for all experiments). Beat-to-beat contractility is inversely influenced by heart rate, so RPP was used as a rate-independent measure of contractility (fig. 2A; effects on rate and pressure are not shown separately in the figures). Cocaine infusion induced a dose-dependent reduction of RPP in both groups (P  < 0.0001; F = 79) that was greater in the control group, where mean normalized RPP at 100 μM cocaine was reduced to 19% (95% CI: 13–25) of baseline. Pioglitazone treatment exerted a highly significant protective effect against cocaine-induced cardiac depression compared with the control group (P  < 0.002; F = 18) because mean normalized RPP at 100 μM cocaine in this group declined only to 48% (CI: 20–77) of baseline (difference in mean normalized values, 95% CI: 29%, 11–46).
Fig. 2.  Effects of cocaine administration in rat isolated hearts. Rate-pressure product shows monotonic decline with increasing cocaine exposure. However, pioglitazone pretreatment reduced sensitivity to cocaine cardiac depression across all exposure levels (A  ). Line pressure, a measure of coronary vascular resistance, is increased by cocaine infusion, but the effect is substantially less in the pioglitazone-fed group (B  ). SEM is shown; n = 6 for both groups. *P  < 0.05; **P  < 0.01; ***P  < 0.001. RPP = rate-pressure product.
Fig. 2. 
	Effects of cocaine administration in rat isolated hearts. Rate-pressure product shows monotonic decline with increasing cocaine exposure. However, pioglitazone pretreatment reduced sensitivity to cocaine cardiac depression across all exposure levels (A 
	). Line pressure, a measure of coronary vascular resistance, is increased by cocaine infusion, but the effect is substantially less in the pioglitazone-fed group (B 
	). SEM is shown; n = 6 for both groups. *P 
	< 0.05; **P 
	< 0.01; ***P 
	< 0.001. RPP = rate-pressure product.
Fig. 2.  Effects of cocaine administration in rat isolated hearts. Rate-pressure product shows monotonic decline with increasing cocaine exposure. However, pioglitazone pretreatment reduced sensitivity to cocaine cardiac depression across all exposure levels (A  ). Line pressure, a measure of coronary vascular resistance, is increased by cocaine infusion, but the effect is substantially less in the pioglitazone-fed group (B  ). SEM is shown; n = 6 for both groups. *P  < 0.05; **P  < 0.01; ***P  < 0.001. RPP = rate-pressure product.
×
Because KRB perfusion rates were held constant throughout the experiments, the perfusion line pressure provides a measure of coronary vascular resistance. Line pressure was dramatically increased in a dose dependent manner by infusion of cocaine in both control and test hearts (P  < 0.0001; F = 163) for the overall cocaine effect; (figure 2B). However, this effect was smaller in the pioglitazone group, for which overall line pressure was significantly less than in controls (P  = 0.05; F = 5.0 for the difference between groups). At 100 μM, cocaine mean line pressure in the pioglitazone group was 113 mmHg (95% CI: 88–138), a 59% increase over baseline, versus  148 mmHg (95% CI: 136–60), an 89% increase, in the control group (difference in mean values, 95% CI: 35 mmHg, 8.4–61.0). In addition, 10 μM phentolamine was infused in two hearts receiving 100 μM cocaine to determine whether cocaine-induced coronary vasoconstriction was caused by α-adrenergic effects. In both cases, mean line pressures measured in the 2 min before and after infusion of phentolamine were indistinguishable (data not shown).
Lusitropy, as measured by the cardiac relaxation time constant (τ), was strongly affected by cocaine infusion (fig. 3A). Cocaine caused a significant, dose-dependent increase in τ (P  < 0.0001; F = 31 for overall cocaine effect in both groups). This effect was observed in control hearts at concentrations as low as 10 μM cocaine, and mean τ (0.072 s; 95% CI: 0.066–0.078) was prolonged 96% at 100 μM cocaine. However, the time constants in hearts from rats fed pioglitazone were significantly shorter than were those of control hearts (P  = 0.017; F = 8.1 for the difference between groups) across the range of tested cocaine concentrations. τ was increased from baseline values by only 40% at 100 μM cocaine in the pioglitazone-treated group (mean, 0.047 s; 95% CI: 0.031–0.063), giving a difference in mean values of 0.025 s (95% CI: 0.0117–0.038). Cocaine similarly increased left ventricular end-diastolic pressure in a dose-dependent manner (fig. 3B; P  < 0.0006; F = 7.7). This effect was attenuated in the pioglitazone-treated hearts, for which overall end-diastolic pressures were lower than that of the controls (P  = 0.043; F = 5.4), and at 100 μM cocaine were increased to a mean of 10.8 mmHg (95% CI: 5.3–16.4) or an 11% increase over baseline values. However, the end-diastolic pressure in control hearts was increased 89% over baseline, to a mean of 19.8 mmHg (CI: 14.1–25.6). The difference in means was 9.0 mmHg (95% CI: 2.70–15.3).
Fig. 3.  Diastolic dysfunction from cocaine exposure. Cardiac relaxation time constant (τ) (A  ) and left ventricular end-diastolic pressure (B  ) are both increased by cocaine administration, but the effect is attenuated for both parameters by pioglitazone pretreatment. Error bars indicate SEM; n = 6 for both groups. **P  < 0.01; ***P  < 0.001.
Fig. 3. 
	Diastolic dysfunction from cocaine exposure. Cardiac relaxation time constant (τ) (A 
	) and left ventricular end-diastolic pressure (B 
	) are both increased by cocaine administration, but the effect is attenuated for both parameters by pioglitazone pretreatment. Error bars indicate SEM; n = 6 for both groups. **P 
	< 0.01; ***P 
	< 0.001.
Fig. 3.  Diastolic dysfunction from cocaine exposure. Cardiac relaxation time constant (τ) (A  ) and left ventricular end-diastolic pressure (B  ) are both increased by cocaine administration, but the effect is attenuated for both parameters by pioglitazone pretreatment. Error bars indicate SEM; n = 6 for both groups. **P  < 0.01; ***P  < 0.001.
×
Metabolism
NA:
Hearts
Baseline rates of oxygen consumption were the same in both groups (n = 6 for all oxygen and lactate studies). However, the baseline (i.e  ., before cocaine infusion) effluent lactate concentration was greater in the pioglitazone-treated hearts than in the control group (0.074 ± 0.007 vs  . 0.048 ± 0.004 mM; mean ± SEM; P  = 0.012). Repeated measures two-way ANOVA showed that oxygen consumption was reduced in a dose dependent manner by cocaine infusion (P  < 0.0001, F = 140 for the effect of cocaine in both treatment groups; fig. 4A). However, there was no overall between-group difference in the effect of cocaine on oxygen consumption (P  = 0.23). Although cocaine per se  had no effect overall on lactate production (P  = 0.52), there was an increase in lactate production in hearts from pioglitazone-treated rats compared with those of controls (P  = 0.008, F = 8.0; fig. 4B).
Fig. 4.  Metabolic effects of cocaine exposure. Cocaine causes dose-dependent reduction in oxygen consumption in both groups (A  ). Lactate production is relatively independent of cocaine concentration in both groups (P  = 0.53; n = 5 for both groups) (B  ). However, lactate production was increased with pioglitazone treatment at baseline (before cocaine exposure; comparison with control group by unpaired, two-tailed t  test with Welch's correction; P  = 0.012) and over the entire range of cocaine concentrations (P  = 0.008, comparison by repeated measures, two-way ANOVA).
Fig. 4. 
	Metabolic effects of cocaine exposure. Cocaine causes dose-dependent reduction in oxygen consumption in both groups (A 
	). Lactate production is relatively independent of cocaine concentration in both groups (P 
	= 0.53; n = 5 for both groups) (B 
	). However, lactate production was increased with pioglitazone treatment at baseline (before cocaine exposure; comparison with control group by unpaired, two-tailed t 
	test with Welch's correction; P 
	= 0.012) and over the entire range of cocaine concentrations (P 
	= 0.008, comparison by repeated measures, two-way ANOVA).
Fig. 4.  Metabolic effects of cocaine exposure. Cocaine causes dose-dependent reduction in oxygen consumption in both groups (A  ). Lactate production is relatively independent of cocaine concentration in both groups (P  = 0.53; n = 5 for both groups) (B  ). However, lactate production was increased with pioglitazone treatment at baseline (before cocaine exposure; comparison with control group by unpaired, two-tailed t  test with Welch's correction; P  = 0.012) and over the entire range of cocaine concentrations (P  = 0.008, comparison by repeated measures, two-way ANOVA).
×
Cell Culture
H9C2 rat ventricular myocytes showed significant increases in lactate production after 4 h exposure to 20 μM pioglitazone (P  < 0.0001; F = 119), whereas a 4-h exposure to cocaine had no effect on lactate production at 30 μM or 300 μM in either group (fig. 5; P  = 0.52; F = 0.7).
Fig. 5.  Lactate production in cultured H9C2 rat ventricular cardiomyocytes. Isolated cardiac muscle cells generated greater lactate concentrations with pioglitazone treatment, but concentrations were not significantly affected by cocaine. *** Difference with paired control was P  < 0.001 in all three treated groups.
Fig. 5. 
	Lactate production in cultured H9C2 rat ventricular cardiomyocytes. Isolated cardiac muscle cells generated greater lactate concentrations with pioglitazone treatment, but concentrations were not significantly affected by cocaine. *** Difference with paired control was P 
	< 0.001 in all three treated groups.
Fig. 5.  Lactate production in cultured H9C2 rat ventricular cardiomyocytes. Isolated cardiac muscle cells generated greater lactate concentrations with pioglitazone treatment, but concentrations were not significantly affected by cocaine. *** Difference with paired control was P  < 0.001 in all three treated groups.
×
Discussion
Our key findings are that cocaine selectively impairs metabolism of an acylcarnitine substrate and that a diet supplemented with pioglitazone, a peroxisome proliferator-activated receptor-γ agonist drug, reduces the adverse effects of cocaine on cardiac function in the isolated heart. Pioglitazone is an oral hypoglycemic agent that improves cellular glucose utilization. Attenuation of cocaine's adverse effects on rate-pressure product, lusitropy, and coronary vascular resistance strongly suggests that pioglitazone also exerts an overall protective effect on myocardial metabolism and function. Increased lactate production in cultured myocytes and isolated hearts treated with pioglitazone indicates that increased glycolytic flux could explain its protective effect. We postulate that inhibition of mitochondrial acylcarnitine exchange could contribute to cocaine cardiac toxicity and infer that metabolic modulation designed to improve substrate utilization could improve cardiac function in cocaine overdose.
The contractile depression and diastolic dysfunction of severe cocaine intoxication are traditionally viewed as a result of combined coronary and systemic vasoconstriction that reduce myocardial oxygen delivery while increasing left ventricular after-load.1,3,14 Interventions that enhance myocardial metabolism (e.g  ., by increasing substrate delivery or utilization) should improve decrements in cardiac function caused by oxidative stressors.15 This prediction is supported by the finding that pioglitazone protected against cocaine-induced impairments in contractility and lusitropy, both energy-dependent elements of excitation-contraction coupling.
Our data suggest a metabolic component for both the cocaine-induced reductions in myocardial performance and their attenuation with thiazolidinedione pretreatment. This connection is supported by the observation that coronary vascular resistance was much less affected by cocaine infusion in hearts from pioglitazone-fed rats than those from controls. Cocaine is an indirect vasoconstrictor and increases, in a dose dependent manner, coronary perfusion pressures in control hearts under constant flow conditions. This effect was significantly reduced by pioglitazone. Pioglitazone treatment typically reduces systolic blood pressure in patients by a few Torr16 but has not been reported to exert direct or indirect effects on coronary vessels. Buchanan et al  . reported that pioglitazone blunted the contractile response of aortic rings to norepinephrine in vitro  but did not alter the resting tension of intact or denuded rings.17 Moreover, baseline values of line pressure were not different in our two groups (P  = 0.32 by two-tailed t  test, n = 6 for both groups). Therefore, it is unlikely that a direct, dilatory effect of pioglitazone on coronary arteries would account for the observed differences in response of line pressure to cocaine treatment. Coronary vascular tone is tightly regulated by metabolic activity: increased myocardial metabolism causes local coronary vasodilation, whereas reduced metabolism causes vasoconstriction.18 Therefore, cocaine-induced reductions in oxidative metabolism could contribute to coronary vasoconstriction and would be reversed by the insulin-sensitizing properties of pioglitazone. This prediction was confirmed by the observations that (1) pioglitazone treatment blunted cocaine-induced vasoconstriction, and (2) α-adrenergic blockade by phentolamine did not prevent cocaine-induced increases in line pressure. These findings suggest an alternative explanation for the well-described phenomenon of cocaine-induced coronary vasoconstriction.
Cocaine is reported to inhibit electron transport and reduce mitochondrial transmembrane potential.19,20 A recent study also reported that chronic cocaine-induced cardiac dysfunction may be caused by an uncoupling effect on oxidative phosphorylation.21 Inhibiting any of these components of oxidative phosphorylation would reduce adenosine triphosphate concentrations in metabolically active tissues such as the heart and therefore result in the same phenotype of poor contractility and delayed or incomplete left ventricular relaxation that results from acute ischemia. Although reoxygenating ischemic tissues is a primary goal of acute surgical or medical intervention in coronary occlusion, optimizing metabolic efficiency is another potential target for treating oxidative stress caused by lack of oxygen or substrate utilization.22,23 Thiazolidinediones potently improve glycolytic flux, and we postulate that pioglitazone treatment effectively protects against the functional myocardial depression caused by these metabolic deficits.
Metabolic strategies for improving cardiac performance in ischemia have been highly effective in both experimental and clinical settings.24–26 For instance, inhibiting β-oxidation of fatty acids is useful in reducing signs and symptoms of ischemia and heart failure because the heart switches to carbohydrate substrate as fuel, which is more efficient in terms of moles of adenosine triphosphate produced per mole of oxygen consumed than is fatty acid oxidation.27 A converse metabolic approach seeks to increase adenosine triphosphate synthesis from glycolysis when it is limited by lack of oxygen or inhibition of substrate transport or oxidation. This represents the biochemical rationale behind insulin and glucose infusion for the treatment of myocardial infarction, a therapeutic strategy dating back four decades and still being investigated.28 Thiazolidinediones represent a chronic insulin-sensitizing pharmacologic intervention that parallels the physiologic mechanism underlying acute administration of glucose and insulin. This therapeutic equivalence has been demonstrated by reports that pioglitazone enhances functional recovery and attenuates ventricular remodeling after myocardial infarction in a murine model29 and that rosiglitazone can protect the heart from ischemia/reperfusion injury.30 
We previously showed that thiazolidinediones increase glucose uptake and lactate production in cultured rodent glioma cells.7,31 They also increased the mitochondrial transmembrane potential and exhibited cytoprotective effects during substrate deprivation.32,33 In the current study, we similarly found that treatment with pioglitazone increased lactate production in cultured cells and isolated hearts. This could result from chronically increased glycolytic flux caused by enhanced glucose uptake, which would provide additional adenosine triphosphate through substrate-level phosphorylation. It is also possible that secondary mechanisms not mediated by direct peroxisome proliferator-activated receptor-γ activation or insulin sensitivity contribute to enhanced lactate production.34 
This study identifies an alternative hypothesis for the cardiotoxic effects of cocaine, namely inhibition of mitochondrial lipid substrate utilization. This hypothesis is further supported by the protective effect of pretreatment with a drug that improves carbohydrate metabolism. Thiazolidinediones are widely used as oral hypoglycemic agents for treating type 2 diabetes. This study points to the potential benefit of metabolic strategies for modulating substrate oxidation and adenosine triphosphate synthesis in cocaine overdose.
References
Lange RA, Cigarroa RG, Yancy CW Jr, Willard JE, Popma JJ, Sills MN, McBride W, Kim AS, Hillis LD: Cocaine-induced coronary-artery vasoconstriction. N Engl J Med 1989; 321:1557–62Lange, RA Cigarroa, RG Yancy, CW Willard, JE Popma, JJ Sills, MN McBride, W Kim, AS Hillis, LD
Billman GE: Cocaine: A review of its toxic actions on cardiac function. Crit Rev Toxicol 1995; 25:113–32Billman, GE
Morcos NC, Fairhurst A, Henry WL: Direct myocardial effects of cocaine. Cardiovasc Res 1993; 27:269–73Morcos, NC Fairhurst, A Henry, WL
Weinberg GL, Palmer JW, VadeBoncouer TR, Zuechner MB, Edelman G, Hoppel CL: Bupivacaine inhibits acylcarnitine exchange in cardiac mitochondria. Anesthesiology 2000; 92:523–8Weinberg, GL Palmer, JW VadeBoncouer, TR Zuechner, MB Edelman, G Hoppel, CL
Lehmann JM, Moore LB, Smith-Oliver TA, Wilkison WO, Willson TM, Kliewer SA: An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma). J Biol Chem 1995; 270:12953–6Lehmann, JM Moore, LB Smith-Oliver, TA Wilkison, WO Willson, TM Kliewer, SA
Rasouli N, Raue U, Miles LM, Lu T, Di Gregorio GB, Elbein SC, Kern PA: Pioglitazone improves insulin sensitivity through reduction in muscle lipid and redistribution of lipid into adipose tissue. Am J Physiol Endocrinol Metab 2005; 288:E930–4Rasouli, N Raue, U Miles, LM Lu, T Di Gregorio, GB Elbein, SC Kern, PA
Dello Russo C, Gavrilyuk V, Weinberg G, Almeida A, Bolanos JP, Palmer J, Pelligrino D, Galea E, Feinstein DL: Peroxisome proliferator-activated receptor gamma thiazolidinedione agonists increase glucose metabolism in astrocytes. J Biol Chem 2003; 278:5828–36Dello Russo, C Gavrilyuk, V Weinberg, G Almeida, A Bolanos, JP Palmer, J Pelligrino, D Galea, E Feinstein, DL
Brunmair B, Staniek K, Gras F, Scharf N, Althaym A, Clara R, Roden M, Gnaiger E, Nohl H, Waldhäusl W, Fürnsinn C: Thiazolidinediones, like metformin, inhibit respiratory complex I: A common mechanism contributing to their antidiabetic actions? Diabetes 2004; 53:1052–9Brunmair, B Staniek, K Gras, F Scharf, N Althaym, A Clara, R Roden, M Gnaiger, E Nohl, H Waldhäusl, W Fürnsinn, C
Feinstein DL, Galea E, Gavrilyuk V, Brosnan CF, Whitacre CC, Dumitrescu-Ozimek L, Landreth GE, Pershadsingh HA, Weinberg G, Heneka MT: Peroxisome proliferator-activated receptor-gamma agonists prevent experimental autoimmune encephalomyelitis. Ann Neurol 2002; 51:694–702Feinstein, DL Galea, E Gavrilyuk, V Brosnan, CF Whitacre, CC Dumitrescu-Ozimek, L Landreth, GE Pershadsingh, HA Weinberg, G Heneka, MT
Palmer JW, Tandler B, Hoppel CL: Biochemical properties of subsarcolemmal and interfibrillar mitochondria isolated from rat cardiac muscle. J Biol Chem 1977; 252:8731–9Palmer, JW Tandler, B Hoppel, CL
Liu D, Hariman RJ, Bauman JL: Cocaine concentration-effect relationship in the presence and absence of lidocaine: Evidence of competitive binding between cocaine and lidocaine. J Pharmacol Exp Ther 1996; 276:568–77Liu, D Hariman, RJ Bauman, JL
Crumb WJ Jr, Clarkson CW: Characterization of cocaine-induced block of cardiac sodium channels. Biophys J 1990; 57:589–99Crumb, WJ Clarkson, CW
Mittleman RE, Wetli CV: Death caused by recreational cocaine use. An update. JAMA 1984; 252:1889–93Mittleman, RE Wetli, CV
Rump AF, Theisohn M, Klaus W: The pathophysiology of cocaine cardiotoxicity. Forensic Sci Int 1995; 71:103–15Rump, AF Theisohn, M Klaus, W
Pitts WR, Lange RA, Cigarroa JE, Hillis LD: Cocaine-induced myocardial ischemia and infarction: Pathophysiology, recognition, and management. Prog Cardiovasc Dis 1997; 40:65–76Pitts, WR Lange, RA Cigarroa, JE Hillis, LD
Dormandy JA, Charbonnel B, Eckland DJ, Erdmann E, Massi-Benedetti M, Moules IK, Skene AM, Tan MH, Lefèbvre PJ, Murray GD, Standl E, Wilcox RG, Wilhelmsen L, Betteridge J, Birkeland K, Golay A, Heine RJ, Korányi L, Laakso M, Mokán M, Norkus A, Pirags V, Podar T, Scheen A, Scherbaum W, Schernthaner G, Schmitz O, Skrha J, Smith U, Taton J, PROactive investigators: Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): A randomised controlled trial. Lancet 2005; 366:1279–89Dormandy, JA Charbonnel, B Eckland, DJ Erdmann, E Massi-Benedetti, M Moules, IK Skene, AM Tan, MH Lefèbvre, PJ Murray, GD Standl, E Wilcox, RG Wilhelmsen, L Betteridge, J Birkeland, K Golay, A Heine, RJ Korányi, L Laakso, M Mokán, M Norkus, A Pirags, V Podar, T Scheen, A Scherbaum, W Schernthaner, G Schmitz, O Skrha, J Smith, U Taton, J
Buchanan TA, Meehan WP, Jeng YY, Yang D, Chan TM, Nadler JL, Scott S, Rude RK, Hsueh WA: Blood pressure lowering by pioglitazone. Evidence for a direct vascular effect. J Clin Invest 1995; 96:354–60Buchanan, TA Meehan, WP Jeng, YY Yang, D Chan, TM Nadler, JL Scott, S Rude, RK Hsueh, WA
Powell JR, Feigl EO: Carotid sinus reflex coronary vasoconstriction during controlled myocardial oxygen metabolism in the dog. Circ Res 1979; 44:44–51Powell, JR Feigl, EO
Yuan C, Acosta D Jr: Effect of cocaine on mitochondrial electron transport chain evaluated in primary cultures of neonatal rat myocardial cells and in isolated mitochondrial preparations. Drug Chem Toxicol 2000;23:339–48Yuan, C Acosta, D
Devi BG, Chan AW: Impairment of mitochondrial respiration and electron transport chain enzymes during cocaine-induced hepatic injury. Life Sci 1997; 60:849–55Devi, BG Chan, AW
Vergeade A, Mulder P, Vendeville-Dehaudt C, Estour F, Fortin D, Ventura-Clapier R, Thuillez C, Monteil C: Mitochondrial impairment contributes to cocaine-induced cardiac dysfunction: Prevention by the targeted antioxidant MitoQ. Free Radic Biol Med 2010; 49:748–56Vergeade, A Mulder, P Vendeville-Dehaudt, C Estour, F Fortin, D Ventura-Clapier, R Thuillez, C Monteil, C
Zhou L, Cabrera ME, Okere IC, Sharma N, Stanley WC: Regulation of myocardial substrate metabolism during increased energy expenditure: Insights from computational studies. Am J Physiol Heart Circ Physiol 2006; 291:H1036–46Zhou, L Cabrera, ME Okere, IC Sharma, N Stanley, WC
Svedjeholm R, Håkanson E, Szabó Z: Metabolic intervention for the ischemic and post-ischemic heart. Wien Klin Wochenschr 1999; 111:501–11Svedjeholm, R Håkanson, E Szabó, Z
Diaz R: Metabolic modulation of acute myocardial infarction. Crit Care Clin 2001; 17:469–76Diaz, R
Díaz R, Paolasso EA, Piegas LS, Tajer CD, Moreno MG, Corvalán R, Isea JE, Romero G: Metabolic modulation of acute myocardial infarction. The ECLA (Estudios Cardiológicos Latinoamérica) Collaborative Group. Circulation 1998; 98:2227–34Díaz, R Paolasso, EA Piegas, LS Tajer, CD Moreno, MG Corvalán, R Isea, JE Romero, G
Stanley WC, Lopaschuk GD, Hall JL, McCormack JG: Regulation of myocardial carbohydrate metabolism under normal and ischaemic conditions. Potential for pharmacological interventions. Cardiovasc Res 1997; 33:243–57Stanley, WC Lopaschuk, GD Hall, JL McCormack, JG
McCormack JG, Stanley WC, Wolff AA: Ranolazine: A novel metabolic modulator for the treatment of angina. Gen Pharmacol 1998; 30:639–45McCormack, JG Stanley, WC Wolff, AA
Weinberg G, VadeBoncouer T: Improved energetics may explain the favorable effect of insulin infusion on bupivacaine cardiotoxicity. Anesth Analg 2001; 92:1075–6Weinberg, G VadeBoncouer, T
Shiomi T, Tsutsui H, Hayashidani S, Suematsu N, Ikeuchi M, Wen J, Ishibashi M, Kubota T, Egashira K, Takeshita A: Pioglitazone, a peroxisome proliferator-activated receptor-gamma agonist, attenuates left ventricular remodeling and failure after experimental myocardial infarction. Circulation 2002; 106:3126–32Shiomi, T Tsutsui, H Hayashidani, S Suematsu, N Ikeuchi, M Wen, J Ishibashi, M Kubota, T Egashira, K Takeshita, A
Khandoudi N, Delerive P, Berrebi-Bertrand I, Buckingham RE, Staels B, Bril A: Rosiglitazone, a peroxisome proliferator-activated receptor-gamma, inhibits the Jun NH(2)-terminal kinase/activating protein 1 pathway and protects the heart from ischemia/reperfusion injury. Diabetes 2002; 51:1507–14Khandoudi, N Delerive, P Berrebi-Bertrand, I Buckingham, RE Staels, B Bril, A
Spagnolo A, Glick RP, Lin H, Cohen EP, Feinstein DL, Lichtor T: Prolonged survival of mice with established intracerebral glioma receiving combined treatment with peroxisome proliferator-activated receptor-gamma thiazolidinedione agonists and interleukin-2-secreting syngeneic/allogeneic fibroblasts. J Neurosurg 2007; 106:299–305Spagnolo, A Glick, RP Lin, H Cohen, EP Feinstein, DL Lichtor, T
Golfman LS, Wilson CR, Sharma S, Burgmaier M, Young ME, Guthrie PH, Van Arsdall M, Adrogue JV, Brown KK, Taegtmeyer H: Activation of PPARgamma enhances myocardial glucose oxidation and improves contractile function in isolated working hearts of ZDF rats. Am J Physiol Endocrinol Metab 2005; 289:E328–36Golfman, LS Wilson, CR Sharma, S Burgmaier, M Young, ME Guthrie, PH Van, Arsdall Adrogue, JV Brown, KK Taegtmeyer, H
Honda T, Kaikita K, Tsujita K, Hayasaki T, Matsukawa M, Fuchigami S, Sugiyama S, Sakashita N, Ogawa H, Takeya M: Pioglitazone, a peroxisome proliferator-activated receptor-gamma agonist, attenuates myocardial ischemia-reperfusion injury in mice with metabolic disorders. J Mol Cell Cardiol 2008; 44:915–26Honda, T Kaikita, K Tsujita, K Hayasaki, T Matsukawa, M Fuchigami, S Sugiyama, S Sakashita, N Ogawa, H Takeya, M
Feinstein DL, Spagnolo A, Akar C, Weinberg G, Murphy P, Gavrilyuk V, Dello Russo C: Receptor-independent actions of PPAR thiazolidinedione agonists: Is mitochondrial function the key? Biochem Pharmacol 2005; 70:177–88Feinstein, DL Spagnolo, A Akar, C Weinberg, G Murphy, P Gavrilyuk, V Dello Russo, C
Fig. 1.  Cocaine impairs lipid-based respiration. Mean values are plotted, and error bars indicate SEM. *P  < 0.05; n = 6 for both groups.
Fig. 1. 
	Cocaine impairs lipid-based respiration. Mean values are plotted, and error bars indicate SEM. *P 
	< 0.05; n = 6 for both groups.
Fig. 1.  Cocaine impairs lipid-based respiration. Mean values are plotted, and error bars indicate SEM. *P  < 0.05; n = 6 for both groups.
×
Fig. 2.  Effects of cocaine administration in rat isolated hearts. Rate-pressure product shows monotonic decline with increasing cocaine exposure. However, pioglitazone pretreatment reduced sensitivity to cocaine cardiac depression across all exposure levels (A  ). Line pressure, a measure of coronary vascular resistance, is increased by cocaine infusion, but the effect is substantially less in the pioglitazone-fed group (B  ). SEM is shown; n = 6 for both groups. *P  < 0.05; **P  < 0.01; ***P  < 0.001. RPP = rate-pressure product.
Fig. 2. 
	Effects of cocaine administration in rat isolated hearts. Rate-pressure product shows monotonic decline with increasing cocaine exposure. However, pioglitazone pretreatment reduced sensitivity to cocaine cardiac depression across all exposure levels (A 
	). Line pressure, a measure of coronary vascular resistance, is increased by cocaine infusion, but the effect is substantially less in the pioglitazone-fed group (B 
	). SEM is shown; n = 6 for both groups. *P 
	< 0.05; **P 
	< 0.01; ***P 
	< 0.001. RPP = rate-pressure product.
Fig. 2.  Effects of cocaine administration in rat isolated hearts. Rate-pressure product shows monotonic decline with increasing cocaine exposure. However, pioglitazone pretreatment reduced sensitivity to cocaine cardiac depression across all exposure levels (A  ). Line pressure, a measure of coronary vascular resistance, is increased by cocaine infusion, but the effect is substantially less in the pioglitazone-fed group (B  ). SEM is shown; n = 6 for both groups. *P  < 0.05; **P  < 0.01; ***P  < 0.001. RPP = rate-pressure product.
×
Fig. 3.  Diastolic dysfunction from cocaine exposure. Cardiac relaxation time constant (τ) (A  ) and left ventricular end-diastolic pressure (B  ) are both increased by cocaine administration, but the effect is attenuated for both parameters by pioglitazone pretreatment. Error bars indicate SEM; n = 6 for both groups. **P  < 0.01; ***P  < 0.001.
Fig. 3. 
	Diastolic dysfunction from cocaine exposure. Cardiac relaxation time constant (τ) (A 
	) and left ventricular end-diastolic pressure (B 
	) are both increased by cocaine administration, but the effect is attenuated for both parameters by pioglitazone pretreatment. Error bars indicate SEM; n = 6 for both groups. **P 
	< 0.01; ***P 
	< 0.001.
Fig. 3.  Diastolic dysfunction from cocaine exposure. Cardiac relaxation time constant (τ) (A  ) and left ventricular end-diastolic pressure (B  ) are both increased by cocaine administration, but the effect is attenuated for both parameters by pioglitazone pretreatment. Error bars indicate SEM; n = 6 for both groups. **P  < 0.01; ***P  < 0.001.
×
Fig. 4.  Metabolic effects of cocaine exposure. Cocaine causes dose-dependent reduction in oxygen consumption in both groups (A  ). Lactate production is relatively independent of cocaine concentration in both groups (P  = 0.53; n = 5 for both groups) (B  ). However, lactate production was increased with pioglitazone treatment at baseline (before cocaine exposure; comparison with control group by unpaired, two-tailed t  test with Welch's correction; P  = 0.012) and over the entire range of cocaine concentrations (P  = 0.008, comparison by repeated measures, two-way ANOVA).
Fig. 4. 
	Metabolic effects of cocaine exposure. Cocaine causes dose-dependent reduction in oxygen consumption in both groups (A 
	). Lactate production is relatively independent of cocaine concentration in both groups (P 
	= 0.53; n = 5 for both groups) (B 
	). However, lactate production was increased with pioglitazone treatment at baseline (before cocaine exposure; comparison with control group by unpaired, two-tailed t 
	test with Welch's correction; P 
	= 0.012) and over the entire range of cocaine concentrations (P 
	= 0.008, comparison by repeated measures, two-way ANOVA).
Fig. 4.  Metabolic effects of cocaine exposure. Cocaine causes dose-dependent reduction in oxygen consumption in both groups (A  ). Lactate production is relatively independent of cocaine concentration in both groups (P  = 0.53; n = 5 for both groups) (B  ). However, lactate production was increased with pioglitazone treatment at baseline (before cocaine exposure; comparison with control group by unpaired, two-tailed t  test with Welch's correction; P  = 0.012) and over the entire range of cocaine concentrations (P  = 0.008, comparison by repeated measures, two-way ANOVA).
×
Fig. 5.  Lactate production in cultured H9C2 rat ventricular cardiomyocytes. Isolated cardiac muscle cells generated greater lactate concentrations with pioglitazone treatment, but concentrations were not significantly affected by cocaine. *** Difference with paired control was P  < 0.001 in all three treated groups.
Fig. 5. 
	Lactate production in cultured H9C2 rat ventricular cardiomyocytes. Isolated cardiac muscle cells generated greater lactate concentrations with pioglitazone treatment, but concentrations were not significantly affected by cocaine. *** Difference with paired control was P 
	< 0.001 in all three treated groups.
Fig. 5.  Lactate production in cultured H9C2 rat ventricular cardiomyocytes. Isolated cardiac muscle cells generated greater lactate concentrations with pioglitazone treatment, but concentrations were not significantly affected by cocaine. *** Difference with paired control was P  < 0.001 in all three treated groups.
×